This event begins in
  • Days
  • Hours
  • Minutes
A zoom link will be available the day of this event.
  • November 6, 2025
  • 6:30 PM EST

National Cornerstone Corner, 6:30 PM

National Cornerstone Corner, 6:30 PM

MONJUVI + rituximab & lenalidomide: the first and only CD19- and CD20-targeted immunotherapy combination approved for 2L+ follicular lymphoma patients

Program Chairs

Dr. Yair Levy

Sponsors

 

This program is not CME accredited.
In addition to the Program's educational offerings, a separate portion involves market research sessions for which a fair market value honorarium will be offered to eligible registrants who choose to participate. Additional details are listed on the registration page and dependent on registrant's designation.